26 September 2022 – Adapted from the Lung Ambition Alliance website. The GLCC is one of the founding partners of the LAA, whose aim is to transform patient care for people diagnosed with lung cancer.

The Challenge

There remains considerable variation in the management of lung cancer around the world. Access for patients to important diagnostics, treatments and support programs varies markedly.

Our Solution

ILC2: Initiatives in Lung Cancer Care, a Global Funding Opportunity to Transform Patient Care and Improve the Patient Experience

The ILC2 program supports patient and caregiver organizations registered as non-profit in their country to propose and conduct projects that can potentially transform patient care in countries around the world.

The program recognizes the high variation in lung cancer management around the world, and the very specific local barriers to quality care that must be considered when developing patient centric solutions to address them.

Over the last 3 years, projects from 21 countries have been granted support to address various points along the patient journey. Please click here read more about the awarded projects: https://www.lungambitionalliance.com/our-initiatives/initiatives-in-lung-cancer-care.html

This year, in addition to support for projects which will transform care for non-small cell lung cancer patients throughout their journey, we are able to make additional grants to focus on innovations in the care of patients with small cell lung cancer.

Round 4 is Now Open!

Full details of the eligibility and priorities for the grant program are provided in the detailed Guidance for Applicants below. You must read this before starting your application.

Guidance for applicants

Start a new application

Grant portal to return to in-progress applications or existing grants only

PLEASE NOTE: All applications must be completed by 19 October 2022.

ILC2 grant applications are reviewed and selected by the four founding partners of the Lung Ambition Alliance: the Global Lung Cancer Coalition, Guardant Health, the International Association for the Study of Lung Cancer and AstraZeneca. Funding for the ILC2 grant is provided by AstraZeneca.

Disclaimer: Grants funding is open to any charitable and registered non-profit organizations involved in the care of patients with lung cancer.  The Grants process is supported by the Charities Aid Foundation (CAF).  When applying, applicants will be directed to CAF’s carefully selected service provider (Blackbaud) to enter your details. Data provided will only be used for the purposes of assessing your organisation’s suitability for this program and to inform you of related services provided by Charities Aid Foundation (CAF) and its partners, where such consent has been provided. Please refer to the Privacy Policies of CAF and Blackbaud or more information on how any data provided will be used.